Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

380

Participants

Timeline

Start Date

February 6, 2018

Primary Completion Date

June 20, 2022

Study Completion Date

June 30, 2027

Conditions
Prostate Cancer
Interventions
DRUG

Nivolumab & Ipilimumab

"Combination Therapy: Cohort 1: Nivolumab 1 mg/kg + ipilimumab 3 mg/kg every 3 weeks for a maximum of 4 cycles . Cohort 2 : Nivolumab 3mg/kg + ipilimumab 1mg/kg every 3 weeks for a maximum of 4 cycles.~Treatment free gap after last combination dose : Cohort 1: 6 weeks; Cohort 2: 3 weeks~Monotherapy: 480 mg flat dose of nivolumab every 4 weeks for up to 10 cycles, or until progression, unacceptable toxicity or withdrawal of consent"

Trial Locations (1)

Unknown

University College London Hospital, London

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

University College, London

OTHER